2026 Q1 -tulosraportti
Vain PDF
23 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 071 | - | - | ||
| 2 006 | - | - | ||
| 243 | - | - | ||
| 401 | - | - | ||
| 2 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenA rights issue means that existing shareholders get the opportunity to buy new shares cheaper than the market price so that the company can raise capital. In Dicot's case: * 13 unit rights (UR) give the right to buy 1 unit * 1 unit costs 1,36 kr * each unit contains: * 8 new shares * 2 TO7-options If you owned Dicot shares on the record date, you automatically received unit rights in your account. ⸻ How to do it? On Nordnet: 1. Go to: * Menu * Corporate Actions / IPO 2. Select: * Dicot Pharma – New Issue 3. Select account/custody account 4. Click: * Participate / Subscribe 5. Choose how many units you want to subscribe for 6. Make sure there is money in the account 7. Confirm Done. ⸻ What happens if you DON'T do anything? Then: * the unit rights expire * you get diluted * your ownership stake in the company decreases. ⸻ Advantages of subscribing 1. You retain your ownership stake You are not diluted as much. ⸻ 2. You get to buy cheap shares The issue takes place at a low price compared to historical levels. ⸻ 3. You get TO7-options The options can become very valuable if: * the studies succeed * the share rises sharply. ⸻ 4. Lower average cost basis (GAV) If you buy cheaper shares, your average price is often lowered. ⸻ Disadvantages / risks 1. You have to invest more money You increase exposure to a high-risk biotech company. ⸻ 2. Clinical risk If future studies fail, the share price can fall sharply. ⸻ 3. More issues may come Biotech companies often need more capital before commercialization. ⸻ What happens in case of a positive outcome? If: * phase 2b is strong * LIB-01 shows clear effect * partnership agreements come then the share can rise very sharply. The important thing is that those who subscribed to the issue then: * own more shares * have more options * and thus much greater exposure to the upside. ⸻ Simplified example Person A does not subscribe Owns: * 100 000 shares Gets diluted. ⸻ Person B subscribes fully Owns after issue: * significantly more shares * plus TO7-options. If the share later goes: * 0,20 kr → 5 kr then the difference in total value will be enormous. ⸻ Important to understand This is no guarantee of profit. You are actually investing in: * the probability that LIB-01 succeeds in larger studies. If the studies succeed, the upside can be very large. If they fail, the share can fall sharply.
·19 t sittenVery clear overview. It was appreciated by someone like me who has never participated in a new share issue. The only thing I'm a bit uncertain about is precisely the risk that this will be repeated several times in the future. Hoping for good results u and that the finances will resolve themselves in a bättrre way for us investors going forward.
·1 päivä sittensell now trust me! 7 years without anything is crazy
·19 t sittenI don't think you understand what this company is doing. The stock will swing wildly several more times as long as the studies are not completely finished and the drug is approved. Until then, this is equivalent to a scratch lottery ticket. But the odds are significantly better today than 7 years ago.- ·2 päivää sittenAm I thinking right here? 100360 unit rights ÷ 13 = 7720 units
·2 päivää sittenWhat does this new issue mean? You will be allocated unit rights based on the shares you owned on 19.05.2026. One unit contains: 8 new shares (AK) 2 subscription options (TO7) If you: exercise the rights → retain approximately the same ownership stake do not exercise them → you will be diluted do nothing → the bank will try to sell your rights
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
23 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenA rights issue means that existing shareholders get the opportunity to buy new shares cheaper than the market price so that the company can raise capital. In Dicot's case: * 13 unit rights (UR) give the right to buy 1 unit * 1 unit costs 1,36 kr * each unit contains: * 8 new shares * 2 TO7-options If you owned Dicot shares on the record date, you automatically received unit rights in your account. ⸻ How to do it? On Nordnet: 1. Go to: * Menu * Corporate Actions / IPO 2. Select: * Dicot Pharma – New Issue 3. Select account/custody account 4. Click: * Participate / Subscribe 5. Choose how many units you want to subscribe for 6. Make sure there is money in the account 7. Confirm Done. ⸻ What happens if you DON'T do anything? Then: * the unit rights expire * you get diluted * your ownership stake in the company decreases. ⸻ Advantages of subscribing 1. You retain your ownership stake You are not diluted as much. ⸻ 2. You get to buy cheap shares The issue takes place at a low price compared to historical levels. ⸻ 3. You get TO7-options The options can become very valuable if: * the studies succeed * the share rises sharply. ⸻ 4. Lower average cost basis (GAV) If you buy cheaper shares, your average price is often lowered. ⸻ Disadvantages / risks 1. You have to invest more money You increase exposure to a high-risk biotech company. ⸻ 2. Clinical risk If future studies fail, the share price can fall sharply. ⸻ 3. More issues may come Biotech companies often need more capital before commercialization. ⸻ What happens in case of a positive outcome? If: * phase 2b is strong * LIB-01 shows clear effect * partnership agreements come then the share can rise very sharply. The important thing is that those who subscribed to the issue then: * own more shares * have more options * and thus much greater exposure to the upside. ⸻ Simplified example Person A does not subscribe Owns: * 100 000 shares Gets diluted. ⸻ Person B subscribes fully Owns after issue: * significantly more shares * plus TO7-options. If the share later goes: * 0,20 kr → 5 kr then the difference in total value will be enormous. ⸻ Important to understand This is no guarantee of profit. You are actually investing in: * the probability that LIB-01 succeeds in larger studies. If the studies succeed, the upside can be very large. If they fail, the share can fall sharply.·19 t sittenVery clear overview. It was appreciated by someone like me who has never participated in a new share issue. The only thing I'm a bit uncertain about is precisely the risk that this will be repeated several times in the future. Hoping for good results u and that the finances will resolve themselves in a bättrre way for us investors going forward.
- ·1 päivä sittensell now trust me! 7 years without anything is crazy·19 t sittenI don't think you understand what this company is doing. The stock will swing wildly several more times as long as the studies are not completely finished and the drug is approved. Until then, this is equivalent to a scratch lottery ticket. But the odds are significantly better today than 7 years ago.
- ·2 päivää sittenAm I thinking right here? 100360 unit rights ÷ 13 = 7720 units
- ·2 päivää sittenWhat does this new issue mean? You will be allocated unit rights based on the shares you owned on 19.05.2026. One unit contains: 8 new shares (AK) 2 subscription options (TO7) If you: exercise the rights → retain approximately the same ownership stake do not exercise them → you will be diluted do nothing → the bank will try to sell your rights
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 071 | - | - | ||
| 2 006 | - | - | ||
| 243 | - | - | ||
| 401 | - | - | ||
| 2 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
23 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenA rights issue means that existing shareholders get the opportunity to buy new shares cheaper than the market price so that the company can raise capital. In Dicot's case: * 13 unit rights (UR) give the right to buy 1 unit * 1 unit costs 1,36 kr * each unit contains: * 8 new shares * 2 TO7-options If you owned Dicot shares on the record date, you automatically received unit rights in your account. ⸻ How to do it? On Nordnet: 1. Go to: * Menu * Corporate Actions / IPO 2. Select: * Dicot Pharma – New Issue 3. Select account/custody account 4. Click: * Participate / Subscribe 5. Choose how many units you want to subscribe for 6. Make sure there is money in the account 7. Confirm Done. ⸻ What happens if you DON'T do anything? Then: * the unit rights expire * you get diluted * your ownership stake in the company decreases. ⸻ Advantages of subscribing 1. You retain your ownership stake You are not diluted as much. ⸻ 2. You get to buy cheap shares The issue takes place at a low price compared to historical levels. ⸻ 3. You get TO7-options The options can become very valuable if: * the studies succeed * the share rises sharply. ⸻ 4. Lower average cost basis (GAV) If you buy cheaper shares, your average price is often lowered. ⸻ Disadvantages / risks 1. You have to invest more money You increase exposure to a high-risk biotech company. ⸻ 2. Clinical risk If future studies fail, the share price can fall sharply. ⸻ 3. More issues may come Biotech companies often need more capital before commercialization. ⸻ What happens in case of a positive outcome? If: * phase 2b is strong * LIB-01 shows clear effect * partnership agreements come then the share can rise very sharply. The important thing is that those who subscribed to the issue then: * own more shares * have more options * and thus much greater exposure to the upside. ⸻ Simplified example Person A does not subscribe Owns: * 100 000 shares Gets diluted. ⸻ Person B subscribes fully Owns after issue: * significantly more shares * plus TO7-options. If the share later goes: * 0,20 kr → 5 kr then the difference in total value will be enormous. ⸻ Important to understand This is no guarantee of profit. You are actually investing in: * the probability that LIB-01 succeeds in larger studies. If the studies succeed, the upside can be very large. If they fail, the share can fall sharply.·19 t sittenVery clear overview. It was appreciated by someone like me who has never participated in a new share issue. The only thing I'm a bit uncertain about is precisely the risk that this will be repeated several times in the future. Hoping for good results u and that the finances will resolve themselves in a bättrre way for us investors going forward.
- ·1 päivä sittensell now trust me! 7 years without anything is crazy·19 t sittenI don't think you understand what this company is doing. The stock will swing wildly several more times as long as the studies are not completely finished and the drug is approved. Until then, this is equivalent to a scratch lottery ticket. But the odds are significantly better today than 7 years ago.
- ·2 päivää sittenAm I thinking right here? 100360 unit rights ÷ 13 = 7720 units
- ·2 päivää sittenWhat does this new issue mean? You will be allocated unit rights based on the shares you owned on 19.05.2026. One unit contains: 8 new shares (AK) 2 subscription options (TO7) If you: exercise the rights → retain approximately the same ownership stake do not exercise them → you will be diluted do nothing → the bank will try to sell your rights
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 071 | - | - | ||
| 2 006 | - | - | ||
| 243 | - | - | ||
| 401 | - | - | ||
| 2 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt